1. Phosphatidic <scp>acid‐</scp> PKA signaling regulates p38 and <scp>ERK1</scp> /2 functions in ligand‐independent EGFR endocytosis
- Author
-
Jorge Cancino, Claudia Oyanadel, Jonathan Barra, Claudio Retamal, Alfonso González, Andrea Soza, Guangwei Du, Juan Jung, and Claudia Metz
- Subjects
MAPK/ERK pathway ,MAP Kinase Signaling System ,Endosome ,p38 mitogen-activated protein kinases ,Endocytic cycle ,Phosphatidic Acids ,Cell Biology ,Phosphatidic acid ,Biology ,Ligands ,Endocytosis ,Biochemistry ,Clathrin ,Cell biology ,ErbB Receptors ,chemistry.chemical_compound ,chemistry ,Structural Biology ,LDL receptor ,Genetics ,Phosphorylation ,Molecular Biology ,Signal Transduction - Abstract
Ligand-independent EGFR endocytosis is inducible by a variety of stress conditions converging upon p38 kinase. A less known pathway involves phosphatidic acid signaling towards the activation of type 4 phosphodiesterases (PDE4) that decrease cAMP levels and PKA activity. This PA/PDE4/PKA pathway induces clathrin-dependent and clathrin-independent endocytosis followed by reversible accumulation of EGFR in recycling endosomes. Here we give further evidence of this PA/PDE4/PKA pathway using biosensors of PA, cAMP and PKA in living cells. Propranolol used to inhibit PA hydrolysis triggers this pathway, which then activates p38 and ERK1/2 downstream PKA inhibition. Clathrin-silencing and IN/SUR experiments involved the activity of p38 in the clathrin-dependent route, while ERK1/2 mediates clathrin-independent EGFR endocytosis. The PA/PDE4/PKA pathway selectively increased the EGFR endocytic rate without affecting LDLR and TfR constitute endocytosis. This selectiveness is likely due to EGFR phosphorylation, as detected in Thr1047/1047 and Ser669 residues. However, EGFR accumulates at perinuclear recycling endosomes colocalizing with TfR, fluorescent transferrin and Rab11, while a small proportion distributes to Alix-endosomes. This indicates a recycling arrest, which includes includes LDLR and TfR in a reversible manner. The PA/PDE4/PKA pathway involving both p38 and ERK1/2 expands the possibilities of EGFR transmodulation and interference in cancer. This article is protected by copyright. All rights reserved.
- Published
- 2021